Related Experiment Videos
Comparative clinical study of josamycin and erythromycin in pertussis
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy
|August 1, 1984
Abstract:
Forty children with pertussis were treated in a randomized trial with josamycin or erythromycin. The pathogen was isolated in 15 cases by immunofluorescent antibody (IFA) technique. The clinical response of both groups was good and comparable. A 15-day course of therapy was able to eradicate the pathogen in all but one patient. Three patients showed minor side effects: diarrhea (2), rash (1).
Insights
Josamycin and erythromycin effectively treated pertussis in children, with both antibiotics showing comparable clinical responses. A 15-day treatment eradicated the bacteria in most cases, with minimal side effects observed.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Pertussis, a highly contagious respiratory infection, poses a significant threat to pediatric populations.
- Antibiotic therapy is crucial for managing pertussis and preventing its spread.
Purpose of the Study:
- To compare the efficacy and safety of josamycin versus erythromycin in treating pediatric pertussis.
- To assess the pathogen eradication rates following a 15-day antibiotic course.
Main Methods:
- A randomized controlled trial involving 40 children diagnosed with pertussis.
- Pathogen identification using the immunofluorescent antibody (IFA) technique in 15 cases.
- Clinical response and side effects were monitored for both treatment groups.
Main Results:
- Both josamycin and erythromycin demonstrated comparable and favorable clinical responses in children with pertussis.
- A 15-day therapeutic regimen successfully eradicated the pertussis pathogen in all but one patient.
- Minor adverse events, including diarrhea and rash, were reported in only three patients.
Conclusions:
- Josamycin and erythromycin are effective treatment options for pediatric pertussis.
- The 15-day treatment course is highly effective in pathogen eradication with a good safety profile.
- Further research may explore optimal treatment durations and comparative effectiveness in diverse pediatric groups.